Business Context and Reporting Period
This Form 8-K reports on the Annual Meeting of Stockholders held by Anavex Life Sciences Corp. on May 23, 2023. The filing details the voting results for director elections and the ratification of the independent registered accounting firm.
Key Financial Metrics
This filing is a current report regarding corporate governance events and does not contain financial statements. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.
Material Changes
No material financial changes are reported in this filing. The document focuses solely on the outcomes of the stockholder vote.
Outlook, Risks, and Management Commentary
The filing confirms the successful election of six directors and the ratification of Grant Thornton LLP as the independent auditor. No specific guidance, risk factors, or management commentary regarding future operations or financial outlook is included in this report.
Investor Verification Checklist
- Meeting Attendance: Verify that 52,088,606 shares (approximately 65% of outstanding stock) were present or represented by proxy.
- Director Election Results: Confirm the vote counts for the six elected directors:
- Christopher Missling, PhD: 24,844,203 For
- Claus van der Velden, PhD: 20,966,462 For
- Athanasios Skarpelos: 23,250,832 For
- Jiong Ma, PhD: 25,109,638 For
- Steffen Thomas, PhD: 25,236,805 For
- Peter Donhauser, D.O.: 25,186,408 For
- Auditor Ratification: Note that Grant Thornton LLP was ratified with 51,086,713 votes For, 709,931 Against, and 291,962 Abstain.
- Broker Non-Votes: Observe that 25,349,339 broker non-votes were recorded for the director election proposals.